Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2

Ken Maes, Elizabeta Nemeth, G. David Roodman, Alissa Huston, Flavia Esteve, Cesar Freytes, Natalie Callander, Eirini Katodritou, Lisa Tussing-Humphreys, Seth Rivera, Karin Vanderkerken, Alan Lichtenstein, Tomas Ganz

Blood (2010) 116 (18): 3635–3644.

https://doi.org/10.1182/blood-2010-03-274571

Published: 2010

Includes: Supplemental data

Journal Articles

Characterization of Hepcidin-Inducing Cytokines in Multiple Myeloma.

Ken Maes, Alissa Huston, MD, David Roodman, MD, PhD, Seth Rivera, MD, PhD, Elizabeta Nemeth, PhD, Alan Lichtenstein, MD, Karin Vanderkerken, PhD, Tomas Ganz, MD, PhD

Blood (2009) 114 (22): 2001.

https://doi.org/10.1182/blood.V114.22.2001.2001

Published: 2009

Journal Articles

Suppression of Mesenchymal Stromal Cell (MSC) Differentiation in Multiple Myeloma (MM) Is Restricted to the Osteoblast Lineage

Flavi a Esteve, MD, Chang Sook Hong, PhD, Alissa Huston, MD, Veronica Garcia Palacios, DDS, PhD, Judy Anderson, Ken Patrene, David Roodman, MD, PhD

Blood (2008) 112 (11): 2752.

https://doi.org/10.1182/blood.V112.11.2752.2752

Published: 2008

Journal Articles

Hepcidin Overproduction Mediates the Anemia of Multiple Myeloma.

Sanjai Sharma, MD, Elizabeta Nemeth, Ph.D, Yi-Hsiang Chen, MD, Alissa Huston, MD, G.D. Roodman, MD, Julia Goodnough, Tomas Ganz, MD, Alan Lichtenstein, MD

Blood (2006) 108 (11): 516.

https://doi.org/10.1182/blood.V108.11.516.516

Published: 2006

Journal Articles

Herpes-Simplex Thymidine Kinase Gene as a Selective Marker in Evaluating the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Alissa Huston, MD, Ganwei Lu, MD, Judy Anderson, BS, Ken Patrene, BS, Lily Hong, MD, Lori Ehrlich, PhD, David Roodman, MD, PhD

Blood (2006) 108 (11): 510.

https://doi.org/10.1182/blood.V108.11.510.510

Published: 2006

Journal Articles

Molecular Mechanisms Regulating Migration and Adhesion in Response to the Chemokine SDF-1 in Multiple Myeloma (MM).

Irene Ghobrial, MD, Ujjal Singha, PhD, Yazan Alsayed, MD, Alissa Huston, MD, Lanie Francis, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD

Blood (2005) 106 (11): 2491.

https://doi.org/10.1182/blood.V106.11.2491.2491

Published: 2005

Journal Articles

Proteomic Analysis of Post Transplant Lymphoproliferative Disorders (PTLD) Using Nanoscale Protein Microarray Techniques.

Yazan Alsayed, MD, Alexey Leontovich, PhD, Michael Timm, BS, Mona Melhem, MD, Michael Nalesnik, MD, Diane George, BS, Ujjal Singha, PhD, Alissa Huston, MD, Lanie Francis, MD, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Ronald Herberman, MD, Irene M. Ghobrial, MD

Blood (2005) 106 (11): 286.

https://doi.org/10.1182/blood.V106.11.286.286

Published: 2005

Journal Articles

The Role of the CXCR4 Inhibitor AMD3100 in Multiple Myeloma (MM).

Irene M. Ghobrial, MD, Mona Melhem, Ujjal Singha, PhD, Diane George, PhD, Michael Timm, Lanie Francis, MD, Yazan Alsayed, MD, Alissa Huston, MD, G. D. Roodman, MD, PhD

Blood (2005) 106 (11): 2492.

https://doi.org/10.1182/blood.V106.11.2492.2492

Published: 2005

Journal Articles

Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD).

Yazan Alsayed, MD, Ujjal Singha, PhD, Lanie Francis, MD, Alissa Huston, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene Ghobrial, MD

Blood (2005) 106 (11): 2413.

https://doi.org/10.1182/blood.V106.11.2413.2413

Published: 2005

Journal Articles

Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative Disorders (PTLD).

Yazan Alsayed, MD, Ujjal Singha, PhD, Lanie Francis, MD, Alissa Huston, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene M. Ghobrial, MD

Blood (2005) 106 (11): 2414.

https://doi.org/10.1182/blood.V106.11.2414.2414

Published: 2005

Journal Articles

The Effect of Rapamycin, 17-AAG and the Combination on the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Lanie Francis, MD, Judy Anderson, BS, Michael Timm, BS, Noriyoshi Kurihara, PhD, Ujjal Singha, PhD, Yazan Alsayed, MD, Alissa Huston, MD, Suzanne Lentzsch, MD, PhD, G. David Roodman, MD, PhD, Irene M. Ghobrial, MD

Blood (2005) 106 (11): 3476.

https://doi.org/10.1182/blood.V106.11.3476.3476

Published: 2005

Journal Articles

Proteomic Analysis Identifies Differences in Multiple Myeloma (MM) Cells Sensitive and Resistant to AKT Inhibition.

Alissa Huston, MD, Alexey Leontovich, MD, Michael Timm, MD, Yazan Alsayed, MD, Ujjal Singha, PhD, Lanie Francis, MD, Ganwei Lu, PhD, Judy Anderson, Suzanne Lentzsch, MD, Irene Ghobrial, MD

Blood (2005) 106 (11): 3402.

https://doi.org/10.1182/blood.V106.11.3402.3402

Published: 2005

Journal Articles

Combination of the AKT Inhibitor Perifosine with the HSP90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin (17-DMAG) Has Synergistic Activity in Multiple Myeloma (MM).

Alissa Huston, MD, Lanie Francis, MD, Yazan Alsayed, MD, Ujjal Singha, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene Ghobrial, MD

Blood (2005) 106 (11): 1592.

https://doi.org/10.1182/blood.V106.11.1592.1592

Published: 2005

Journal Articles

Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) Using Nanoscale Protein Micorarray Techniques.

Yazan Alsayed, MD, Michael Timm, MD, Alexey Leontovich, MD, Daniel Santos, MD, Allen Ho, MD, Ujjal Singha, PhD, Lanie Francis, MD, Alissa Huston, MD, Ganwei Lu, MD, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Leleu Xavier, MD, Steven Treon, MD, PhD, Irene M. Ghobrial, MD

Blood (2005) 106 (11): 504.

https://doi.org/10.1182/blood.V106.11.504.504

Published: 2005

Journal Articles

Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia.

Irene M. Ghobrial, MD, Mona Melhem, MD, Ujjal Singha, PhD, Diane George, Michael Timm, MD, Lanie Francis, MD, Yazan Alsayed, MD, Alissa Huston, MD, G. David Roodman, MD, PhD, Philip Greipp, MD, Morie Gertz, MD, Thomas Witzig, MD

Blood (2005) 106 (11): 993.

https://doi.org/10.1182/blood.V106.11.993.993

Published: 2005

Journal Articles

The Role of the AKT Inhibitor Perifosine in Migration and Adhesion in Multiple Myeloma (MM).

Alissa Huston, MD, Ujjal Singha, PhD, Yazan Alsayed, MD, Lanie Francis, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene M. Ghobrial, MD

Blood (2005) 106 (11): 2509.

https://doi.org/10.1182/blood.V106.11.2509.2509

Published: 2005

NARROW

In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2

Characterization of Hepcidin-Inducing Cytokines in Multiple Myeloma.

Suppression of Mesenchymal Stromal Cell (MSC) Differentiation in Multiple Myeloma (MM) Is Restricted to the Osteoblast Lineage

Hepcidin Overproduction Mediates the Anemia of Multiple Myeloma.

Herpes-Simplex Thymidine Kinase Gene as a Selective Marker in Evaluating the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Molecular Mechanisms Regulating Migration and Adhesion in Response to the Chemokine SDF-1 in Multiple Myeloma (MM).

Proteomic Analysis of Post Transplant Lymphoproliferative Disorders (PTLD) Using Nanoscale Protein Microarray Techniques.

The Role of the CXCR4 Inhibitor AMD3100 in Multiple Myeloma (MM).

Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD).

Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative Disorders (PTLD).

The Effect of Rapamycin, 17-AAG and the Combination on the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Proteomic Analysis Identifies Differences in Multiple Myeloma (MM) Cells Sensitive and Resistant to AKT Inhibition.

Combination of the AKT Inhibitor Perifosine with the HSP90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin (17-DMAG) Has Synergistic Activity in Multiple Myeloma (MM).

Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) Using Nanoscale Protein Micorarray Techniques.

Role of the Chemokine Receptor CXCR4 in Waldenstrom Macroglobulinemia.

The Role of the AKT Inhibitor Perifosine in Migration and Adhesion in Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only